Heterogeneity of estrogen binding sites in mouse mammary cancer

Cheryl S. Watson, James H. Clark

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The recent demonstration in our laboratory of at least two specific estrogen binding sites in the rat uterus prompted us to investigate similar heterogeneity of binding sites in a trans-plantable ovarian dependent mouse mammary tumor (MXT-3590). Saturation analysis of cytoplasmic (protamine sulfate or hydroxylapatite exchange assay) or crude nuclear fractions (protamine sulfate precipitated nuclear exchange assay) revealed two binding components: type I which conforms to the classically described estrogen receptor and type II which has a lower affinity for estradiol but a greater capacity than type I sites. Exposure of cytosol to charcoal partially removes bound 3H-estradiol from type II sites but not from type I sites. Type II sites are specific for estrogens and do not translocate from the cytoplasmic to the nuclear compartment. Although Type II sites undergo dissociation on prelabeled sucrose density gradients, they are readily demonstrable by postlabeling sucrose density gradient fractions and hydroxylapatite adsorption. Since the presence of type II sites interferes with the measurement of the estrogen receptor (type I) which may also undergo dissociation on sucrose gradients, we recommended that the technique of postlabeling be used for the sucrose gradient analysis of type I and II sites. In addition, saturation assays should be performed over a wide range of 3H-es-tradiol concentrations (0.1-120 nM) for proper evaluation of both sites. These considerations may contribute to more accurate predictions about the response of breast cancers to endocrine therapies.

Original languageEnglish (US)
Pages (from-to)91-111
Number of pages21
JournalJournal of Receptors and Signal Transduction
Volume1
Issue number1
DOIs
StatePublished - 1980
Externally publishedYes

Fingerprint

Sucrose
Estrogens
Binding Sites
Breast Neoplasms
Assays
Protamines
Durapatite
Estrogen Receptors
Estradiol
Charcoal
Cytosol
Adsorption
Uterus
Rats
Tumors
Demonstrations
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Pharmacology

Cite this

Heterogeneity of estrogen binding sites in mouse mammary cancer. / Watson, Cheryl S.; Clark, James H.

In: Journal of Receptors and Signal Transduction, Vol. 1, No. 1, 1980, p. 91-111.

Research output: Contribution to journalArticle

Watson, Cheryl S. ; Clark, James H. / Heterogeneity of estrogen binding sites in mouse mammary cancer. In: Journal of Receptors and Signal Transduction. 1980 ; Vol. 1, No. 1. pp. 91-111.
@article{7ebb02caf8e5496fa3879c73562148e0,
title = "Heterogeneity of estrogen binding sites in mouse mammary cancer",
abstract = "The recent demonstration in our laboratory of at least two specific estrogen binding sites in the rat uterus prompted us to investigate similar heterogeneity of binding sites in a trans-plantable ovarian dependent mouse mammary tumor (MXT-3590). Saturation analysis of cytoplasmic (protamine sulfate or hydroxylapatite exchange assay) or crude nuclear fractions (protamine sulfate precipitated nuclear exchange assay) revealed two binding components: type I which conforms to the classically described estrogen receptor and type II which has a lower affinity for estradiol but a greater capacity than type I sites. Exposure of cytosol to charcoal partially removes bound 3H-estradiol from type II sites but not from type I sites. Type II sites are specific for estrogens and do not translocate from the cytoplasmic to the nuclear compartment. Although Type II sites undergo dissociation on prelabeled sucrose density gradients, they are readily demonstrable by postlabeling sucrose density gradient fractions and hydroxylapatite adsorption. Since the presence of type II sites interferes with the measurement of the estrogen receptor (type I) which may also undergo dissociation on sucrose gradients, we recommended that the technique of postlabeling be used for the sucrose gradient analysis of type I and II sites. In addition, saturation assays should be performed over a wide range of 3H-es-tradiol concentrations (0.1-120 nM) for proper evaluation of both sites. These considerations may contribute to more accurate predictions about the response of breast cancers to endocrine therapies.",
author = "Watson, {Cheryl S.} and Clark, {James H.}",
year = "1980",
doi = "10.3109/10799898009039256",
language = "English (US)",
volume = "1",
pages = "91--111",
journal = "Journal of Receptor and Signal Transduction Research",
issn = "1079-9893",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Heterogeneity of estrogen binding sites in mouse mammary cancer

AU - Watson, Cheryl S.

AU - Clark, James H.

PY - 1980

Y1 - 1980

N2 - The recent demonstration in our laboratory of at least two specific estrogen binding sites in the rat uterus prompted us to investigate similar heterogeneity of binding sites in a trans-plantable ovarian dependent mouse mammary tumor (MXT-3590). Saturation analysis of cytoplasmic (protamine sulfate or hydroxylapatite exchange assay) or crude nuclear fractions (protamine sulfate precipitated nuclear exchange assay) revealed two binding components: type I which conforms to the classically described estrogen receptor and type II which has a lower affinity for estradiol but a greater capacity than type I sites. Exposure of cytosol to charcoal partially removes bound 3H-estradiol from type II sites but not from type I sites. Type II sites are specific for estrogens and do not translocate from the cytoplasmic to the nuclear compartment. Although Type II sites undergo dissociation on prelabeled sucrose density gradients, they are readily demonstrable by postlabeling sucrose density gradient fractions and hydroxylapatite adsorption. Since the presence of type II sites interferes with the measurement of the estrogen receptor (type I) which may also undergo dissociation on sucrose gradients, we recommended that the technique of postlabeling be used for the sucrose gradient analysis of type I and II sites. In addition, saturation assays should be performed over a wide range of 3H-es-tradiol concentrations (0.1-120 nM) for proper evaluation of both sites. These considerations may contribute to more accurate predictions about the response of breast cancers to endocrine therapies.

AB - The recent demonstration in our laboratory of at least two specific estrogen binding sites in the rat uterus prompted us to investigate similar heterogeneity of binding sites in a trans-plantable ovarian dependent mouse mammary tumor (MXT-3590). Saturation analysis of cytoplasmic (protamine sulfate or hydroxylapatite exchange assay) or crude nuclear fractions (protamine sulfate precipitated nuclear exchange assay) revealed two binding components: type I which conforms to the classically described estrogen receptor and type II which has a lower affinity for estradiol but a greater capacity than type I sites. Exposure of cytosol to charcoal partially removes bound 3H-estradiol from type II sites but not from type I sites. Type II sites are specific for estrogens and do not translocate from the cytoplasmic to the nuclear compartment. Although Type II sites undergo dissociation on prelabeled sucrose density gradients, they are readily demonstrable by postlabeling sucrose density gradient fractions and hydroxylapatite adsorption. Since the presence of type II sites interferes with the measurement of the estrogen receptor (type I) which may also undergo dissociation on sucrose gradients, we recommended that the technique of postlabeling be used for the sucrose gradient analysis of type I and II sites. In addition, saturation assays should be performed over a wide range of 3H-es-tradiol concentrations (0.1-120 nM) for proper evaluation of both sites. These considerations may contribute to more accurate predictions about the response of breast cancers to endocrine therapies.

UR - http://www.scopus.com/inward/record.url?scp=0019156656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019156656&partnerID=8YFLogxK

U2 - 10.3109/10799898009039256

DO - 10.3109/10799898009039256

M3 - Article

C2 - 7299733

AN - SCOPUS:0019156656

VL - 1

SP - 91

EP - 111

JO - Journal of Receptor and Signal Transduction Research

JF - Journal of Receptor and Signal Transduction Research

SN - 1079-9893

IS - 1

ER -